Compare Cassava Sciences Inc (FLNA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PulteGroup, Inc. — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while PulteGroup, Inc. trades at $130.15 (market cap $25.22B). The key difference: PulteGroup, Inc. is far larger — about 528.2× Cassava Sciences Inc's market cap, and PulteGroup, Inc. pays a 0.79% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PHM | |
|---|---|---|
Market Cap | $47.75M | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $142.56 |
52-Week Low | $0.87 | $110.11 |
Enterprise Value | -$34.93M | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
PulteGroup (PHM) trades at $130.05, down 2.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025 and Q1 2026. Recent news highlights operational expansion into Northwest Florida and corporate recognition as a Great Place to Work, while financials indicate solid profitability with an 11.62% net margin and a P/E of 13.53.
Outlook remains cautiously optimistic with a consensus price target of $137.20, suggesting modest upside. Risks include margin pressure from housing market affordability challenges and volatile cash flows. Institutional sentiment leans neutral with 50% hold ratings, reflecting balanced Wall Street views amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
